Eli Lilly and Company, a leader in the pharmaceuticals industry, is recognized for its innovative drug solutions. Despite challenges in the competitive healthcare sector, Eli Lilly exhibits a solid financial standing, making its stock an interesting prospect for investors.
The fundamental metrics of Eli Lilly indicate a moderately strong position with areas requiring attention.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Analysis over time shows consistent performance with minor fluctuations.
| Date | Overall Score | Discounted Cash Flow | Return on Equity | Return on Assets | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-09-12 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| N/A | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Price targets present a bullish outlook, despite some divergence in predictions.
| High | Low | Median | Consensus |
|---|---|---|---|
| 1050 | 700 | 715 | 798 |
The sentiment is predominantly positive, favoring a 'Buy' recommendation.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
Eli Lilly and Company shows a stable financial foundation and positive analyst sentiment, supported by its innovative pharmaceutical portfolio. However, the company's rating for debt to equity and valuation metrics suggests potential financial risks. With a strong market position and optimistic price targets, the stock provides compelling opportunities for investors seeking exposure in the healthcare sector.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.